摘要:
Disclosed are peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, methods of using such analogues to treat mammals and pharmaceutical compositions useful therefor comprising said analogues.
摘要:
Peptide variants of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), in which at least one of the amino acid residues is replaced with Acc.
摘要:
Peptide variants of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), in which at least one of the amino acid residues is replaced with Acc.
摘要:
The invention features a solid, non-particulate, sustained-release pharmaceutical composition for parenteral administration to a patient. The composition consists essentially of (1) a soluble, gelable peptide salt, and (2) up to 30 percent, by weight, of a pharmaceutically acceptable, monomeric, soluble carrier, compounded into a solid cylindrical form, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids, the gel releasing the peptide continuously within the patient over an extended period of at least three days.
摘要:
This invention pertains to a sustained release complex, Compound (I), which comprises Compound (A), having formula (A) or a pharmaceutically acceptable salt thereof and a copolymer comprising poly-(I)-lactic-glycolic-tartaric acid (P(I)LGT), wherein the amino group of said Compound (A) is ionically bound to a carboxyl group of the P(I)LGT. The present invention further pertains to a process for making said substantial release complex. Further still, the present invention is directed to a pharmaceutical composition comprising said sustained release complex and a pharmaceutically acceptable carrier(s).
摘要:
A method of treating hyperprolactinemia in an animal, including a human, administers one or more somatostatin type-5 receptor agonist(s) to, for example, lower abnormally high levels of prolactin in the blood of the animal. A method of treating a subject, including a human, afflicted by a prolactinoma, administers one or more type-5 receptor selective agonist(s) to, for example, lower prolactin secretion and/or decrease tumor size in the subject.